IP Library Granted Patent US 12,559,753
Granted Patent B2
US 12,559,753 · App. 18/509,899 · Granted Feb 24, 2026

RNase inhibitors

Inventors: Nathan Tanner (West Newbury, MA); Jennifer Ong (Salem, MA); Esta Slayton (Epping, NH); Lisa L. Maduzia (Topsfield, MA); Salvatore V. Russello (Newbury, MA)
Assignee: New England Biolabs, Inc.
C12N15/1137C12N9/1247C12N9/1276C12N15/1003C12Q1/6848C12N9/58C12N2310/16C12Y207/07006C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,753
App. No.
18/509,899
Granted
Feb 24, 2026
Kind
B2
Abstract

Compositions, methods and kits are provided that include an inhibitory oligonucleotide RNase inhibitor capable of inhibiting one or more types of RNase that coexist with biological samples or are introduced in the laboratory, thereby protecting RNA in the sample from degradation. More than one type of oligonucleotide RNase inhibitor may be combined in a mixture to inhibit a plurality of different RNases. Single oligonucleotides were identified to have inhibitory activity for a plurality of different RNases. The RNase oligonucleotide inhibitor may be immobilized on beads or other surface. It may be stored in a lyophilized form or in solution.

Claims (15)

1 . A composition, comprising: a mixture comprising two or more single stranded oligonucleotide RNase inhibitors, wherein each RNAse inhibitor inhibits the activity of at least one of RNase A and RNase I, wherein the RNase inhibitors are selected from the group consisting of:

(a) an oligonucleotide having at least 90% sequence identity with a sequence selected from any of SEQ ID NOs: 1-62; and

(b) an oligonucleotide having at least 90% sequence identity with a sequence selected from any of SEQ ID NOs: 1-62, further comprising one or more hydrophobic nucleotide substitutions in the oligonucleotide.

2 . The composition of claim 1 , wherein each oligonucleotide has a sequence corresponding to any of the oligonucleotides of SEQ ID NOs: 1-62, further comprising one or more hydrophobic nucleotide substitutions in the oligonucleotide.

3 . The composition of claim 1 , wherein the one or more hydrophobic nucleotide substitutions are selected from the group consisting of 5-(N-benzylcarboxyamide)-dUTP (BndUTP), 5-(N-isobutylcarboxyamide)-dUTP (iBudUTP), 5-(N-tryptaminocarboxyamide)-dUTP (Trp dUTP), and Napthyl-dU.

4 . The composition of claim 1 , wherein the RNase inhibitors are in solution, immobilized on a matrix, or in powder form resulting from freeze drying or lyophilization of the inhibitor preparation.

5 . The composition of claim 4 , wherein the matrix is selected from the group consisting of beads, a reaction vessel, and a multi-well plate.

6 . The composition of claim 5 , wherein the beads, reaction vessel, or multi-well plate has a polymer surface.

7 . A method for binding at least one of RNase A and RNase I in a sample, comprising: combining the composition of claim 1 , wherein the composition is immobilized on a matrix, with a sample containing at least one of RNAse A and RNAse I.

8 . The method of claim 7 , wherein the sample further comprises RNA and the RNA is protected from degradation by an RNase.

9 . The method of claim 7 , wherein the sample further comprises a reaction mixture for synthesizing RNA.

10 . The method of claim 8 , further comprising reverse transcribing the RNA with a reverse transcriptase to form DNA and optionally amplifying the DNA for subsequent detection, diagnosis of the RNA, purification or sequencing.

11 . The method of claim 8 , wherein the RNA is obtained from a biological sample.

12 . The method of claim 8 , wherein the RNA is one or more RNAs selected from the group consisting of messenger RNA, transfer RNA, ribosomal RNA, microRNA, long non coding RNA, antisense RNA, CRISPR RNA, Piwi interacting RNA, small interfering RNAs, 75K RNA, enhancer RNA, spliced leader RNA, telomerase RNA component, guide RNA, small nuclear RNA, small nucleolar RNA, ectosomal RNA, and viral RNA.

13 . A kit containing a matrix for receiving a sample suspected of containing an RNase, wherein the composition of claim 1 is immobilized on the matrix, and the matrix is suitable for receiving a sample containing RNAse.

Assignments (2)
SECURITY INTEREST Recorded May 29, 2026
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 074795/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2023
From: TANNER, NATHAN; ONG, JENNIFER; SLAYTON, ESTA; MADUZIA, LISA; RUSSELLO, SALVATORE V.
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 065584/0172 →
Continuity (4)
Continuation 17207507 · Mar 19, 2021
Provisional Application 63001417 · Mar 29, 2020
Provisional Application 62992921 · Mar 21, 2020
Related Publication 20240150770A1 · May 9, 2024
References Cited (8)
US 8975388B2 · Zichi et al. · 2015 [cited by applicant]
US 10633644B1 · Chen et al. · 2020 [cited by applicant]
US 20100240550A1 · Jackson · 2010 [cited by applicant]
Tuerk, et al (1990), Science 249 p. 505-10. [cited by applicant]
Blackwell, et al. (1990) Science 250 1104-10. [cited by applicant]
Gold et al.. 2010. PLoS One vol. 5. [cited by applicant]
Stoltenburg, et al. (2015) PLoS One vol. 10. [cited by applicant]
Wu, et al (2016), Methods 106, 21-28. [cited by applicant]